Lv1
48 积分 2025-09-02 加入
Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma
3个月前
已完结
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US
3个月前
已完结
Projecting overall survival in health-economic models: uncertainty and maturity of data
5个月前
已完结
皖公网安备34019202002308
